Bertrand Allen
Chief Scientific Officer Skymab Therapeutics
Bertrand Allard serves as Chief Scientific Officer (CSO) at Skymab Biotherapeutics. Bertrand is a senior immuno-oncology researcher with over 15 years of experience in laboratory research, notably through his fellowship in John Stagg’s lab in Montreal.
Over the years, he acquired a rich background in tumor immunology and pre-clinical drug testing as well as a specific expertise in the development of monoclonal antibodies against GPCRs.
Since joining Skymab in 2020, he has played a crucial role in the advancement of Skymab’s lead ADC program and in the identification of new potential GPCR targets suitable for ADC modality.
Bertrand holds a PhD in immunology from Paris 11 University and an engineering diploma from the Polytechnic School of Nice-Sophia Antipolis. He co-authored over 40 peer-reviewed scientific articles in top-tier journals and his publications have been cited more than 5000 times (h index of 26).
Seminars
- GPCR1 is enriched in multiple types of cancers including solid and heme indications
- SKM104 is a specific anti-GPCR1 antibody with optimal properties for ADC modality
- SKM104-MA-L2 is an anti-GPCR1, exatecan-based ADC showing robust anti-tumour activity in multiple cancer models
